ArticleBMC infectious diseases2026
Histopathological features and eight-week split-tablet sofosbuvir/velpatasvir treatment in young children with acute hepatitis C: a case-series study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
aimsData on the clinical features and treatment of young children with acute hepatitis C (AHC) remain limited. This case-series report describes the clinical characteristics, histopathological findings, and treatment responses of two young children with AHC, aiming to provide insights for future research and clinical practice. We evaluated two four-year-old children who acquired AHC through unsafe injection practices. The clinical decision-making process and management strategies were documented, and both children underwent liver biopsy. They received an eight-week course of sofosbuvir/velpatasvir (200/50 mg; ½ tablet, tablet-split, once daily). The primary efficacy endpoint was sustained virologic response (SVR12), defined as undetectable HCV RNA 12 weeks after completing treatment. Adverse events were monitored throughout the therapy period. Both children were asymptomatic at diagnosis. Baseline HCV RNA levels were 1,500 IU/mL and 2,300 IU/mL, with alanine aminotransferase (ALT) levels of 316 U/L and 15 U/L, respectively. Liver biopsy revealed mild inflammation with moderate fibrosis (G1S2) in child 1 and moderate inflammation with mild fibrosis (G2S1) in child 2. By the first week of therapy, ALT levels normalized in both cases; HCV RNA declined to 49.2 IU/mL in child 1 and became undetectable in child 2. By week 2, HCV RNA was undetectable in child 1. At 12 weeks after treatment completion, both achieved SVR12, with no treatment-related adverse events and stable laboratory parameters throughout.
conclusionsTo our knowledge, this is the first report clearly demonstrating that AHC in young children can cause histological liver injury. An eight-week tablet-split regimen of sofosbuvir/velpatasvir appeared safe, well tolerated, and effective in these two cases. Further studies are warranted to validate these findings in the broader pediatric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.